Inactive Instrument
VG Life Sciences Inc. Stock Other OTC
Stocks
VGLS
US91822T1016
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 2.7M 2.32M 2.18M 1.99M 3.75M 258M 3.76M 25.85M 10.09M 130M 10.13M 9.91M 431M | P/E 2013 * |
-
| P/E 2014 | - |
|---|---|---|---|---|---|
| Enterprise Value | 6.52M 5.62M 5.27M 4.81M 9.06M 624M 9.09M 62.54M 24.4M 315M 24.5M 23.96M 1.04B | EV / Sales 2013 |
-
| EV / Sales 2014 | - |
| Free-Float |
99.36% | Yield 2013 * |
-
| Yield 2014 | - |
| 1 day | +4.00% |
| Manager | Title | Age | Since |
|---|---|---|---|
William Farrand
CEO | Chief Executive Officer | - | - |
Paul Strickland
DFI | Director of Finance/CFO | 50 | 2016-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Paul Strickland
BRD | Director/Board Member | 50 | 2016-12-31 |
William Farrand
BRD | Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.00% | -2.50% | - | - | 435K | |
| -0.78% | -1.42% | +2.49% | +22.78% | 51.14B | |
| -6.76% | -1.37% | +439.07% | +540.42% | 47.4B | |
| -0.26% | +0.80% | +38.77% | +18.08% | 43.19B | |
| -1.96% | -2.49% | +22.55% | +80.69% | 42.35B | |
| -0.31% | -1.75% | +17.23% | +52.37% | 33.23B | |
| -1.20% | -2.34% | +28.18% | +131.70% | 17.07B | |
| -1.02% | -2.10% | - | - | 16.38B | |
| -0.88% | -0.66% | +11.60% | +27.75% | 14.76B | |
| -1.24% | -0.74% | +79.52% | +47.42% | 14.15B | |
| Average | -1.03% | +0.70% | +79.93% | +115.15% | 31.07B | |
| Weighted average by Cap. | -1.89% | +1.12% | +98.44% | +136.92% |
| 2013 | 2014 | |
|---|---|---|
| Net sales | - | - |
| Net income | -7.42M -6.39M -5.99M -5.47M -10.31M -709M -10.34M -71.12M -27.75M -358M -27.86M -27.25M -1.19B | -6.19M -5.33M -5M -4.56M -8.6M -592M -8.63M -59.33M -23.15M -299M -23.24M -22.73M -990M |
| Net Debt | 2.49M 2.15M 2.02M 1.84M 3.47M 238M 3.48M 23.91M 9.33M 120M 9.36M 9.16M 399M | 3.83M 3.3M 3.09M 2.82M 5.32M 366M 5.33M 36.69M 14.31M 185M 14.37M 14.06M 612M |
Employees
-
